FeesSafety
Pluang+

CRB-913 shows significant 5% weight loss in 12 weeks with good safety in Phase 1b obesity trial

Company Fundamentals
16 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
CRB-913 shows significant 5% weight loss in 12 weeks with good safety in Phase 1b obesity trial

Corbus Pharmaceuticals announced positive Phase 1b trial results for CRB-913, an oral obesity drug, showing a 5% mean weight loss at the highest 60 mg dose after 12 weeks with no plateauing. The drug also reduced waist circumference and BMI significantly, with mild and infrequent psychiatric side effects and fewer gastrointestinal issues than similar treatments. The trial involved 254 obese, non-diabetic adults and showed a low 8.3% discontinuation rate due to adverse events. Corbus plans to discuss these results with the FDA and explore combining CRB-913 with other obesity therapies.

Corbus Pharmaceuticals' Phase 1b clinical trial data for CRB-913 is presented here as context for readers. For those tracking the health sector, 67 of 150 US health stocks on Pluang rose while 61 fell as of Nov 16, 2026 19:13 WIB. Notable movers include Medline Inc. Class A (MDLN) down 3.88% at USD 37.94 with a typical hold time of 7 days, ClearPoint Neuro Inc (CLPT) up 3.77% at USD 8.80 with a 13-day hold, and Hims and Hers Health Inc (HIMS) down 3.65% at USD 19.01 with a 24-day hold.

More News

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike is under pressure to clarify its cost-cutting plans as it prepares for its first investor day since 2017, scheduled for November 16–17. Despite efforts led by CEO Elliott Hill to turn the company around, management expects revenue to decline by ...

Market News
Bearish
55 minutes ago
Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric have partnered to create North America's first plug-and-play virtual power plant (VPP) for renters and apartment residents, starting in New York City. This innovative system uses portable power stations plugged into standar...

Market News
Bullish
1 hour ago
P-1 AI names retired Brig. Gen. Matt Isler GM for Aerospace and Defense to boost AI engineering efforts.

P-1 AI names retired Brig. Gen. Matt Isler GM for Aerospace and Defense to boost AI engineering efforts.

P-1 AI has appointed retired Brigadier General Matt Isler as General Manager for its Aerospace and Defense division. Isler brings nearly 30 years of military and industry experience, including leadership roles at Northrop Grumman and startup DEFCON A...

Market News
Bullish
1 hour ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
2 hours ago
GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App